Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 03 2018
revised: 17 05 2018
accepted: 01 06 2018
pubmed: 2 7 2018
medline: 14 6 2019
entrez: 2 7 2018
Statut: ppublish

Résumé

Knowledge of haematological abnormalities in cirrhosis has greatly improved in recent years. To evaluate how Spanish Digestive Disease specialists manage haemostatic alterations and associated disorders in patients with cirrhosis. All members of the Spanish Association for the Study of the Liver and Spanish Society of Digestive Pathology were invited to fill in a web-based questionnaire. 135 professionals, 93 hepatologists and 42 non-hepatologists responded to the survey. The concept of rebalanced haemostasis was known by 74.8% of them. Most specialists corrected the INR and thrombocytopenia before invasive procedures with moderate risk of bleeding or major surgery and in severe gastrointestinal bleeding. The threshold of platelets and, especially, INR used to administer blood products varied greatly. Pharmacological prophylaxis of venous thromboembolism prevailed, but it was highly dependent on the INR and platelet figures. Most participants initiated anticoagulation regardless of the degree of portal vein thrombosis, even in patients ineligible for transplantation. In potential candidates, only 56% maintained it indefinitely or until liver transplantation. No major differences between hepatologists and non-hepatologists were found. A significant variability and certain deviation from current guidelines was observed among Spanish Digestive Disease specialists regarding management of haemostatic alterations and associated disorders in cirrhosis.

Sections du résumé

BACKGROUND
Knowledge of haematological abnormalities in cirrhosis has greatly improved in recent years.
AIMS
To evaluate how Spanish Digestive Disease specialists manage haemostatic alterations and associated disorders in patients with cirrhosis.
METHODS
All members of the Spanish Association for the Study of the Liver and Spanish Society of Digestive Pathology were invited to fill in a web-based questionnaire.
RESULTS
135 professionals, 93 hepatologists and 42 non-hepatologists responded to the survey. The concept of rebalanced haemostasis was known by 74.8% of them. Most specialists corrected the INR and thrombocytopenia before invasive procedures with moderate risk of bleeding or major surgery and in severe gastrointestinal bleeding. The threshold of platelets and, especially, INR used to administer blood products varied greatly. Pharmacological prophylaxis of venous thromboembolism prevailed, but it was highly dependent on the INR and platelet figures. Most participants initiated anticoagulation regardless of the degree of portal vein thrombosis, even in patients ineligible for transplantation. In potential candidates, only 56% maintained it indefinitely or until liver transplantation. No major differences between hepatologists and non-hepatologists were found.
CONCLUSIONS
A significant variability and certain deviation from current guidelines was observed among Spanish Digestive Disease specialists regarding management of haemostatic alterations and associated disorders in cirrhosis.

Identifiants

pubmed: 29960901
pii: S1590-8658(18)30770-9
doi: 10.1016/j.dld.2018.06.003
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

95-103

Informations de copyright

Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Auteurs

José Ignacio Fortea (JI)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain. Electronic address: jifortea@gmail.com.

Ángela Puente (Á)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Iranzu Ezcurra (I)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain.

Antonio Cuadrado (A)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

María Teresa Arias-Loste (MT)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Joaquín Cabezas (J)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Susana Llerena (S)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Paula Iruzubieta (P)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Carlos Rodríguez-Lope (C)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Patricia Huelin (P)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Fernando Casafont (F)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Emilio Fábrega (E)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Javier Crespo (J)

Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Santander, Spain; Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH